|1.||Tamamura, H: 3 articles (05/2001 - 12/2000)|
|2.||Nakashima, H: 3 articles (05/2001 - 12/2000)|
|3.||Fujii, N: 3 articles (05/2001 - 12/2000)|
|4.||Kanamoto, T: 3 articles (05/2001 - 12/2000)|
|5.||Yoshimori, M: 2 articles (05/2001 - 03/2001)|
|6.||Gotoh, K: 2 articles (05/2001 - 03/2001)|
|7.||Kanbara, K: 2 articles (05/2001 - 03/2001)|
|8.||Mitola, Stefania: 1 article (01/2005)|
|9.||Aglietta, Massimo: 1 article (01/2005)|
|10.||Perissinotto, Eliana: 1 article (01/2005)|
05/01/2001 - "We have reported that T134 and T140 inhibited X4 HIV-1 infection specifically because they acted as CXCR4 antagonists. "
03/01/2001 - "We found that the synthetic peptides T134 and T140 (see text for full names) inhibited X4 HIV-1 infection with selectivity and low toxicity because they acted as CXCR4 antagonists. "
03/01/2001 - "However, high concentrations of T134, T140, and ALX40-4C (see text for full name) increased the expression of CCR5 and R5 HIV-1 infection, as did stromal cell-derived factor 1 (SDF-1). "
12/04/2000 - "A polyphemusin peptide analogue, T22 ([Tyr(5,12), Lys7]-polyphemusin II), and its shortened potent analogues, T134 (des-[Cys(8,13), Tyr(9,12)]-[D-Lys10, Pro11, L-citrulline16]-T22 without C-terminal amide) and T140 [[L-3-(2-naphthyl)alanine3]-T134], strongly inhibit the T-cell line-tropic (T-tropic) HIV-1 infection through their specific binding to a chemokine receptor, CXCR4. "
|2.||HIV Infections (HIV Infection)
|3.||Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Leukemia, Pre B Cell)
|4.||Osteosarcoma (Osteogenic Sarcoma)
|5.||Neoplasm Metastasis (Metastasis)
|4.||CXCR4 Receptors (CXCR4 Receptor)
|6.||N-alpha-acetyl-nona-D-arginine amide acetate